Proposals include licensure for community health workers, expanded provider roles, and Medicaid coverage adjustments to address staffing gaps and access barriers.
FDA approves gepotidacin, a first-in-class oral antibiotic, for treating uncomplicated urinary tract infections in females aged 12 and older, based on phase III trial results.
The researchers found that invasive urodynamic testing did not improve outcomes or cost-effectiveness in women with refractory overactive bladder symptoms.
The FDA approves vutrisiran (Amvuttra) as the first RNAi therapeutic to reduce cardiovascular events and mortality in adults with transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.
The FDA's 2025 pulse oximetry guidance introduces stricter accuracy standards, larger study cohorts, and objective skin pigmentation assessment to address measurement bias in darker-skinned patients.